Navigation Links
Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
Date:3/18/2013

hind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking StatementsThis press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, Omeros' expectations that it has sufficient resources to fund operations for at least the next 12 months; that it will submit a New Drug Application and Marketing Authorization Application for OMS302 in 2013; that it will be able to market and sell OMS302 in 2014; when it will be able to announce data from its PDE10 Phase 1 program; that it will advance its MASP-2 and PDE7 programs into this clinic this year; that it will conduct two additional Phase 3 clinical trials evaluating OMS103HP, with enrollment in the first trial beginning in the first half of 2013; and that Omeros may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 18, 2013. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
2. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
3. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
4. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
5. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
6. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
7. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2013
8. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
9. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
10. FibeRio® Technology Corporation Announces Strategic Investment Financing Led by SABIC and Aster Capital
11. Celsion Corporation Announces $15 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 Carahsoft and CDS ... January 23, 2014 at 2pm EST (11am PST), “Natural ... topic focuses on how technology can turn raw, heterogeneous ... for government agencies. The online webinar will last approximately ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in Altadena ... ideas for 2014 in production and sales of interactive ... high-quality, low-cost, DRM-free ebooks and to use the sales ... first major development will be bookstore sales in local ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... is the First Latin American Country to ... Massachusetts, February 13, Shire plc (LSE: SHP)(NASDAQ: ... company, announced that ELAPRASE(R),(idursulfase), a human enzyme ... has been approved for commercial sale by ...
... 2008 Earnings Guidance and Introduces Q1 2008 Guidance, ... (Nasdaq:,CEPH) today reported 2007 sales of $1.727 billion, ... the company,s previously issued,guidance. Basic loss per common ... the previously announced settlement reserve, amortization expense,and certain ...
... Blood Bank,is proud to announce that two-time defending NASCAR ... "We,re honored to have this,NASCAR superstar and terrific person ... of CORD:USE. Jimmie Johnson joins CORD:USE as a,spokesperson to ... "I,m excited about telling people the benefits of ...
Cached Biology Technology:Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome 2Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome 3Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome 4Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 2Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 3Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 4Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 5Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 6Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 7Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 8Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 9Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 10Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 11Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 12Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 13Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 14Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 15Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 16Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance 17Two-time Defending NASCAR Sprint Cup Series Champion Jimmie Johnson Joins the Team at CORD:USE Cord Blood Bank to Help Win the Race for Life 2
(Date:4/20/2014)... known that people with Down syndrome have a heightened ... they haven,t been able to explain why. Now, ... a connection between the two conditions. , In a ... Genetics , the researchers track the genetic chain of ... to the cellular havoc that occurs in ALL. ...
(Date:4/18/2014)... X-ray crystallography and nuclear magnetic resonance imaging (NMR) to ... but such efforts have long been hampered by the ... molecule and often in ordered and crystalized form to ... peer into the structure of most molecules. , Harvard ... thing of the past. , A team of ...
(Date:4/18/2014)... adds a twist to the story of how barnyard chickens ... 21 in the journal Proceedings of the National Academy ... chickens that lived 200-2300 years ago in Europe, researchers report ... have looked far different from the chickens we know today. ... associate with modern domestic chickens -- such as their yellowish ...
Breaking Biology News(10 mins):Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3MRI, on a molecular scale 2MRI, on a molecular scale 3Ancient DNA offers clues to how barnyard chickens came to be 2
... Solutions, a global life sciences technology solutions company ... to announce the latest release of ENLIGHTEN ... ENLIGHTEN system, which provides a proven, highly ... clinical trial management system (CTMS), has effectively supported ...
... University of Tennessee, Knoxville, researchers have found ... an estrogen-like compound in the environment which could ... adversely affect fish, plants and human health. Previously, ... these impacts. Theodore Henry, an adjunct ...
... is pleased to announce the recipients of the 2010 ... Advancement of Biotherapy. The 6 award winners were presented ... in Los Angeles; they are: David Armstrong, MD, DPM, ... MD, MPH; Kosta Mumcuoglu, PhD; and Aletha Tippett, MD, ...
Cached Biology News:MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution 2UT researchers link algae to harmful estrogen-like compound in water 2BTER Foundation announces winners of the William S. Baer Award 2BTER Foundation announces winners of the William S. Baer Award 3
... GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C 14 H ... 6 ,M.W.= 408.63 ,Assay: Greater ... in DMF) ,Biological Activity: Blue color ... Analysis: Agrees with theoretical values ,Thin ...
BD IMagnet 1 each...
... A.P. Johnstone and M.W. Turner ... strategies and methods used in the ... of antibodies in immunoassays, the standardisation ... ELISA techniques including amplification systems, enzyme ...
MitoScreen (JC-1) Kit , 100 tests Consult technical datasheet for details....
Biology Products: